Company Overview and News

5
Filinvest net income rises 27%

2018-05-16 bworldonline
FILINVEST Development Corp. (FDC) delivered a 27% increase in its net income attributable to the parent for the first quarter of 2018, driven mainly by its property unit and investments in the hospitality and leisure sector.
FILIY FVSMF FDC FLI

5
FDC nets P2.8B

2018-05-16 business.inquirer.net
Gotianun-led conglomerate Filinvest Development Corp. grew first quarter net profit by 18 percent year-on-year to P2.8 billion, mostly driven by its property business.
FILIY FVSMF FDC FLI

8
Widus sees $1-billion expansion in Clark

2018-05-07 bworldonline
KOREAN-LED Widus International Leisure, Inc., the operator of the Marriot hotel chain in Clark, Pampanga, is looking at expanding its hotel projects in the city to total to $1 billion in the next few years.
FILIY FVSMF MWP FDC GMRINFRA GMQRY FLI MWIDE 532754

5
Filinvest Land keeps capex steady in 2018

2018-04-22 bworldonline
FILINVEST LAND, Inc. (FLI) is keeping its capital spending steady in 2018, as the Gotianun-led developer aims for at least high single-digit growth boosted by its office segment.
FILIY FVSMF FDC FLI

6
Filinvest Development nets P10.3 billion

2018-04-10 bworldonline
FILINVEST Development Corp. (FDC) grew its net profit by more than a fifth last year, buoyed by its banking and property businesses.
FILIY FVSMF EW FDC FLI

4
FDC nets P10.3B

2018-04-10 business.inquirer.net
Gotianun-led Filinvest Development Corp. (FDC) boosted net profit last year by 21 percent to P10.3 billion, driven by higher earnings from the banking, property and power generation businesses.
FVSMF FLI

5
Gotianun-led FDC to build $200-M casino in Clark

2018-04-05 bworldonline
THE GOTIANUN FAMILY is the latest group to venture into the booming gaming sector after securing a license to build a casino in Pampanga.
FILIY FVSMF FDC FLI

4
Filinvest breaks ground on San Pedro project

2018-03-23 bworldonline
LISTED company Filinvest Land, Inc. recently broke ground on its a mid-income residential project called Southwind, the newest addition to it’s South Peak community development in San Pedro, Laguna.
FVSMF FLI

5
Rental revenues push FLI profit 9% higher in 2017

2018-03-21 bworldonline
FILINVEST Land, Inc. (FLI) grew its earnings by 9% in 2017, fueled by the expansion of its rental business alongside demand for both retail and office spaces.
FVSMF FLI

4
Filinvest Land grows earnings by 9% in 2017

2018-03-21 bworldonline
Filinvest Land, Inc. (FLI) grew its earnings by 9% in 2017, fueled by the expansion of its rental properties alongside demand from both retail and office spaces.
FVSMF FLI

5
FLI nets P5.83B

2018-03-21 business.inquirer.net
Gotianun-led property developer Filinvest Land Inc. (FLI) grew its net profit last year by 9 percent to P5.83 billion on higher rental revenues from its new office and shopping malls.
FVSMF FLI

4
Filinvest’s 100 West wins Best Investment Property Award

2018-03-12 business.inquirer.net
Filinvest Land Inc. adds another feather to its cap as 100 West, a mixed-use development envisioned to be the go-to place where one can lead a multi-faceted lifestyle, won the prestigious Best Investment Property in this year’s Southeast Asia’s Best of the Best Awards by Dot Property, a digital media company that drives a network of nine property portal websites and offline media throughout Asia in recognition of the absolute best projects, developers and companies that contribute to real estate.
FVSMF FLI

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to PSE:FLI / Filinvest Land, Inc. on message board site Silicon Investor.

Netflix (NFLX) FLIR Systems, Inc.
Netflix NFLX Crowflight Minerals
The Conflicted Thread THE CANADIAN BURGER FLIPPERS HOUSE
GameZnFlix Inc. New FLICK PICS
STOCKS FOR THE COMING CONFLICT EFLT - Elite Flight Solutions, Inc.